What is the recommended treatment for peripheral arterial disease?

Treatment for Peripheral Arterial Disease

All patients with symptomatic PAD should receive aspirin 75-100 mg daily or clopidogrel 75 mg daily as antiplatelet therapy, combined with high-intensity statin therapy, supervised exercise training for at least 30-45 minutes three times weekly for minimum 12 weeks, and cilostazol 100 mg twice daily for lifestyle-limiting claudication (unless heart failure is present). 1, 2, 3

Risk Factor Modification

Smoking Cessation

• Mandatory intervention at every visit for all PAD patients who smoke 2
• Offer comprehensive cessation program including:
  • Behavioral modification therapy
  • Pharmacotherapy: varenicline, bupropion, or nicotine replacement therapy 2
  • These are not optional—one or more must be offered unless contraindicated

Lipid Management

• High-intensity statin therapy is required for all PAD patients to reduce cardiovascular events 4
• Target LDL < 3.1 mmol/L (approximately 120 mg/dL) 5
• Consider adding PCSK9 inhibitor if target not achieved 4
• For patients with triglycerides >1.5 mmol/L despite statin therapy, icosapent ethyl 2g twice daily may be added 4

Blood Pressure Control

• Use ACE inhibitors or angiotensin receptor blockers as first-line agents 6
• These provide cardiovascular protection beyond blood pressure reduction in PAD patients

Diabetes Management

• Target hemoglobin A1C <7% 7
• Strongly consider SGLT2 inhibitors for cardiovascular benefit 6
• Daily foot inspection and proper footwear are mandatory 7

Antiplatelet and Antithrombotic Therapy

For Symptomatic PAD (Intermittent Claudication or Critical Limb Ischemia)

Choose ONE of the following strategies:

1. Single antiplatelet therapy (Class I recommendation):

   • Aspirin 75-100 mg daily, OR
   • Clopidogrel 75 mg daily 2, 3
   • Clopidogrel is preferred based on CAPRIE trial showing 23.8% relative risk reduction versus aspirin specifically in PAD patients 7

2. Dual pathway inhibition (for high ischemic risk, non-high bleeding risk):

   • Rivaroxaban 2.5 mg twice daily PLUS aspirin 100 mg daily 4, 6
   • This is particularly recommended after lower-limb revascularization 4

Critical caveats:

• Dual antiplatelet therapy (aspirin + clopidogrel) is NOT recommended routinely—only consider in very high-risk patients not at increased bleeding risk 1
• Warfarin plus antiplatelet therapy is contraindicated—increases bleeding without benefit 1, 3

For Asymptomatic PAD

• Aspirin 75-100 mg daily can be useful if ABI ≤0.90 (Class IIa) 1
• For asymptomatic PAD with diabetes, aspirin may be considered for primary prevention 4
• For borderline ABI (0.91-0.99), antiplatelet benefit is not well established 1

Exercise Therapy

Supervised exercise training (SET) is Class I recommendation 1, 4:

• Minimum 30-45 minutes per session
• At least 3 times per week
• Minimum 12 weeks duration
• Walking to moderate-severe claudication pain 1
• High intensity preferred (77-95% max heart rate or 14-17 on Borg scale) 4

When SET unavailable:

• Structured home-based exercise with monitoring (calls, logbooks, connected devices) is second-line 4
• Unsupervised programs have uncertain effectiveness 1

For patients undergoing revascularization:

• SET is recommended as adjuvant therapy 4

Pharmacotherapy for Claudication Symptoms

First-Line: Cilostazol

• Cilostazol 100 mg twice daily is indicated for all patients with lifestyle-limiting claudication 1
• Absolute contraindication: heart failure 1
• Most effective medication for improving walking distance (Class I, Level A evidence)
• Can be added to antiplatelet therapy 3

Second-Line: Pentoxifylline

• Pentoxifylline 400 mg three times daily may be considered as alternative to cilostazol 1
• Clinical effectiveness is marginal and not well established 1

Not Recommended

• L-arginine: effectiveness not established 1
• Propionyl-L-carnitine: effectiveness not established 1
• Ginkgo biloba: marginal benefit, not established 1
• Chelation therapy (EDTA): NOT indicated and may be harmful 1

Revascularization Strategy

Indications for Intervention

Endovascular or surgical revascularization is indicated when:

1. Vocational or lifestyle-limiting disability from claudication persists after 3 months of optimal medical therapy (OMT) and exercise 1, 4
2. PAD-related quality of life remains impaired after 3-month trial of OMT plus exercise 4
3. Chronic limb-threatening ischemia (CLTI) is present—revascularization for limb salvage 1

Critical principle: Revascularization is NOT recommended solely to prevent progression to CLTI in asymptomatic or mildly symptomatic patients 4

Anatomic Approach

Aortoiliac Disease:

• Endovascular intervention is preferred for TASC A lesions 1
• Stenting is effective as primary therapy for common and external iliac stenosis/occlusion 1
• Provisional stenting for suboptimal balloon angioplasty results 1

Femoropopliteal Disease:

• Drug-eluting treatment (balloons/stents) should be considered first-choice 4
• Open surgical bypass with autologous vein (great saphenous vein) should be considered when available in low surgical risk patients 4
• Primary stenting in femoral/popliteal arteries is NOT recommended 1
• Stents only as salvage for failed angioplasty 1

Below-the-Knee Disease:

• In severe claudication undergoing femoropopliteal intervention, treating BTK arteries may be considered in same session 4

Critical Limb-Threatening Ischemia

• For acute limb ischemia from thrombosis/embolism: surgery is recommended over thrombolysis 3
• For CLTI with rest pain unable to undergo revascularization: prostanoids may be considered 3

Follow-Up and Monitoring

• Regular follow-up at least annually is recommended 4
• Assess PAD-related quality of life at 3 months after initiating OMT and exercise 4
• Monitor for progression of symptoms
• Ensure adherence to medical therapy and risk factor modification

Common pitfall: Many PAD patients are undertreated compared to coronary artery disease patients 8. Ensure all evidence-based therapies are implemented, not just revascularization.